Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Table 4 Contrast-enhanced ultrasound Liver Imaging Reporting and Data System categorization and serum biomarkers of 134 patients

Serum biomarker	CHC		HCC		ICC
	LR-5	LR-M	LR-5	LR-M	LR-5	LR-M
AFP (+) CA19-9 (+)	0	31	0	11	0	11
AFP (-) CA19-9 (-)	5	11	26	5	0	18
AFP (+) CA19-9 (-)	4	111	32	61	0	21
AFP (-) CA19-9 (+)	0	1	0	0	0	8
Total	9	26	58	12	0	29

¹Numbers that diagnosis as combined hepatocellular-cholangiocarcinoma (CHC) according to the diagnostic criteria. Alpha-fetoprotein (AFP) (+) = the elevated level of AFP (> 20 ng/mL), AFP (-) = the normal level of AFP (≤ 20 ng/mL), carbohydrate antigen 19-9 (CA19-9) (+) = the elevated level of CA19-9 (> 100 U/mL), CA19-9 (-) = the normal level of CA19-9 (≤ 100 U/mL). HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; LI-RADS: Liver Imaging Reporting and Data System.